(NP (NP (JJ Glucocorticoid-mediated) (NN inhibition)) (PP (IN of) (NP (NP (NN RANTES) (NN expression)) (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes))))) (. .))
(S (NP-SBJ-51 (DT The) (NN chemokine) (NN RANTES)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (NP (-NONE- *-51)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ allergic) (JJ inflammatory) (NNS diseases)) (PP (VBG including) (NP (NP-COOD (NP (NN asthma)) (CC and) (NP (NN rhinitis))) (SBAR (WHNP-52 (WDT which)) (S (NP-SBJ-53 (-NONE- *T*-52)) (VP (VBP are) (VP (ADVP-TMP (RB frequently)) (VBN treated) (NP (-NONE- *-53)) (PP (IN with) (NP (NNS glucocorticoids)))))))))))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (NP-SBJ (NN dexamethasone)) (ADVP (RB dramatically)) (VP (VBD inhibited) (NP (NN RANTES) (NN mRNA) (NN expression)) (ADVP (NN dose) (RB dependently)) (PP (IN in) (NP-COOD (NP (ADJP (NN anti-CD3) (JJ activated)) (NN Hut-78) (NN T) (NNS cells)) (CC and) (NP (JJ human) (NNS PBMCs)))))))) (. .))
(S (NP-SBJ-54 (NP (NN Inhibition)) (PP (IN of) (NP (NNS RANTES) (NN expression)))) (VP-COOD (VP (VBD did) (RB not) (VP (VB appear) (S (NP-SBJ (-NONE- *-54)) (VP (TO to) (VP (VB be) (ADJP-PRD (JJ secondary) (PP (TO to) (NP (NN IL-2) (NN inhibition))))))))) (CC and) (VP (VBD required) (NP (NP (VBG binding)) (PP (TO to) (NP (DT the) (JJ intracellular) (NN glucocorticoid) (NN receptor)))))) (. .))
(S (NP-SBJ (NP (DT The) (NN down-regulation)) (PP (IN of) (NP (NN RANTES) (NN expression))) (PP (IN by) (NP (NP (NNS glucocorticoids)) (PP (IN in) (NP (NN T) (NNS cells)))))) (VP (MD may) (VP (ADVP (RB directly)) (VB contribute) (PP-COOD (PP (TO to) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN in) (S (NP-SBJ (-NONE- *)) (VP (VBG suppressing) (NP (JJ cellular) (NN infiltration))))))) (CC and) (PP (TO to) (NP (PRP$ their) (JJ anti-inflammatory) (NNS properties)))))) (. .))
